31 results about "Gene transcript" patented technology

The present invention provides systems and methods for cell free RNA sequencing. Targeted sequencing can be performed using a set of gene transcripts that are rare abundance in a population of cell free nucleic acid control samples.

An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

An isolated or purified antisense oligomer (ASO) for modifying pre-mRNA splicing or mRNA translation of one or more of the following proteins encoded by a corresponding gene transcript or portion thereof: S100A8; S100A9; and / or IL1RL2.

Isolated or purified antisense oligomers, combinations, and cocktails for modifying premRNA splicing or mRNA translation in the SOST gene transcript or a portion thereof to induce downregulation of functional SOST protein production. Isolated or purified antisense oligomers are provided, as needed, for inducing the production of proteins with retained or partially retained introns, truncated proteins, proteins lacking functional regions, or a reduction in the total amount of protein produced.

Provided herein are altered cell lines comprising a suspension cell line adapted from an adherent cell line having a different expression profile from a corresponding non-altered adherent cell line, methods for generating altered cell lines, and methods of characterizing altered expression profiles for a gene, a transcript, or a protein in an altered cell line.

The present invention relates to a method for identifying the aging degree of a subject or a tissue or organ thereof, and for evaluating the effect of anti-aging interventions. Specifically, provided is a method for identifying the aging degree of a subject or a cell, tissue or organ thereof, or for evaluating the biological age of the subject or diagnosing premature aging disorders, which method predicts the aging status of a tissue or organ of a subject on the basis of the levels of DNA methylation, gene transcripts, proteins or metabolites. The present invention further relates to the use of metformin in the preparation of a drug for treating, preventing or delaying aging-related diseases or conditions in primates, preferably humans.

Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

The invention relates to the proteins Agrin, Zyxin, Synaptotagmin-5, and combinations thereof, as well as the gene transcripts form the corresponding genes, as biomarkers of a hypoxic-ischemic encephalopathy (HIE).

An isolated or purified antisense oligomer and compositions and mixtures for modifying pre-messenger RNA (pre mRNA) splicing or mRNA translation in a SOST gene transcript or part thereof to induce down regulation of functional SOST protein production.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing or mRNA translation in one or more of the following proteins encoded by the respective gene transcript or part thereof LEPROT; and / or LEPROTL1 which has a modified backbone structure, wherein the antisense oligomer induces downregulation of the production of functional LEPROT and / or LEPROTL1 protein.

The present invention relates to a set of gene transcripts (A) isolated from a set of genes consisting of gene subset (1) consisting of ADM, AXL, BIRC5, CDV3, CRIM1, CTGF, CYR61, FSTL1, GADD45A, KRT8, LMNB2, MATN2, PKP4, RND3, RPS24, SEC14L1, SGK1, SLC25A3, SLC3A2, TNFRSF12A, TPM1, TPX2, and TUBB6; and an isolated set of genes (B) consisting of at least one gene transcript from gene subset (2) consisting of CTSB, FTH1, SQSTM1, TCF25, and UBC, or from a set of genes consisting of DLC1, AKAP2, CANX, SAFB2, EIF4H, NDUFS5, SEPT9, and EIF4A1, as well as their use in a diagnostic method for TEAD-activated cancer.

An isolated or purified antisense oligomer for modulating mRNA translation of the OPA1 gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.

The invention relates to an isolated set of gene transcripts (A) from a set of genes consisting of a subset of genes (1) consisting of ADM, AXL, BIRC5, CDV3, CRIM1, CTGF, CYR61, FSTL1, GADD45A, KRT8, LMNB2, MATN2, PKP4, RND3, RPS24, SEC14L1, SGK1, SLC25A3, SLC3A2, TNFRSF12A, TPM1, TPX2, TUBB6 and of a subset of genes (2) consisting of CTSB, FTH1, SQSTM1, TCF25, UBC, or an isolated set of genes (B) consisting of at least one gene transcript from a set of genes consisting of DLC1, AKAP2, CANX, SAFB2, EIF4H, NDUFS5, SEPT9, and EIF4A1, and their use in diagnostic methods for TEAD-active cancer.

The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of Type VII Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements.

This invention discloses the application of interfering with the expression of the conserved lepidopteran gene LSCG6 in the control of lepidopteran pests. The study found that interfering with LSCG6 in the early stages of silkworm egg development significantly reduces the egg turning rate and affects hatching. Feeding Asian corn borer larvae with LSCG6 dsRNA during their larval stage affects their development, with a 24-hour mortality rate exceeding 90%. Feeding rice stem borer larvae with LSCG6 dsRNA also affects their development, with a 24-hour mortality rate exceeding 40%. The LSCG6 gene of this invention, substances that promote the degradation of the gene transcript, substances that inhibit the synthesis of the gene transcript, or techniques that disrupt the expression of the gene can all be used for the control of lepidopteran pests. This invention provides a new target for the control of lepidopteran pests and provides a theoretical basis for the subsequent development of insecticides targeting this gene.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CFHR genes including CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5, as well as methods of inhibiting expression of CFHR genes including CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5, and methods of treating subjects that would benefit from reduction in expression of CFHR genes including CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5, such as subjects having a CFHR-associated disease, disorder, or condition, using such dsRNA compositions.

The invention discloses a GCKR gene transcript as well as a detection reagent, method and application thereof. The GCKR gene transcript is a nucleic acid molecule capable of coding a protein with an amino acid sequence as shown in SEQ ID NO: 24 and / or SEQ ID NO: 25. The invention provides novel GCKR gene transcripts sGCKR1 and sGCKR2, which can effectively regulate the activity of GCK enzyme and have a good application prospect in the aspect of preparing products for regulating blood sugar.

This invention relates to a blood-derived marker gene combination for identifying early pregnancy status in sika deer, an identification kit, and their applications, belonging to the field of molecular biology detection technology. Addressing the technical problem of the lack of early pregnancy diagnosis methods before embryo implantation in sika deer, and the difficulty in accurately determining pregnancy status, which easily leads to missed opportunities for optimal mating of does, this invention provides a blood-derived marker gene combination for identifying early pregnancy status in sika deer, including… Cbs , Igf2r , xCt and Gclc This invention provides a method for identifying the expression levels of the aforementioned gene transcripts in the peripheral blood of female sika deer 6.5–7.5 days after mating. If the expression levels are significantly upregulated compared to the day of mating, the individual is determined to be pregnant. This invention provides molecular targets for establishing a diagnostic technique for ultra-early pregnancy in sika deer, and the accompanying primers are highly sensitive, specific, and provide stable amplification, enabling timely identification of non-pregnant individuals and subsequent re-mating, thereby improving the reproductive efficiency of sika deer.

Disclosed herein are UNC13A antisense oligonucleotides with modified backbone structures. The disclosed UNC13A oligonucleotides reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

The present invention provides a method for determining the resistance of a microorganism to a drug by detecting at least a transcript of a drug resistance gene from a microorganism in a biological sample, the method comprising the steps of: (i) lysing the cells by means of a chemical or a mechanical method, thereby obtaining a lysate and cell debris; (ii) obtaining a ribosome-antibody complex from the lysate using an antibody or a fragment thereof which binds specifically to a microorganism-ribosomal protein; (iii) purifying the mRNA associated to the ribosome-antibody complex by means of a nucleic acid extraction method; and (iv) submitting the resulting mRNA to a specific gene detection method, thereby identifying the at least one drug resistance gene transcript of the biological sample. Provided methods and kits allow determining the resistance to antibiotics of a biological sample in a rapid and reliable manner, thereby minimizing the risk of AMR and allowing the definition of the therapeutic potential of a selected antibiotic

The invention aims to disclose a histone deacetylase gene GmHDA11 capable of remarkably improving the salt tolerance of soybeans as well as an encoded protein and application of the histone deacetylase gene GmHDA11. The three transcripts of the gene GmHDA11 are GmHDA11 I, GmHDA11 II or GmHDA11 III, and the three transcripts of the gene GmHDA11 are GmHDA11 I, GmHDA11 II or GmHDA11 According to the gene engineering application of the gene GmHDA11 in regulation and control of the soybean salt tolerance, specifically, overexpression of the gene transcript GmHDA11I is conducted, and the soybean salt tolerance is improved. The plant height, the pod number, the grain soybean and the yield of the stable GmHDA11I transgenic soybean are higher than those of a control group, so that the GmHDA11I plays an important role in improving the salt tolerance and the yield of the soybean. The invention provides the molecular marker for identifying the GmHDA11 transcript, and the molecular marker has obvious effects on rapidly screening new salt-resistant and high-yield soybean materials and accelerating salt-resistant and high-yield soybean breeding.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

This invention discloses an engineered mutant CpAgo_PM based on a novel PAZ nucleic acid binding pocket and its applications, belonging to the fields of molecular biology and genetic engineering. The amino acid sequence of the mutant CpAgo_PM is shown in SEQ ID NO.1. This invention rationally designs the PAZ nucleic acid pocket, mutating some normally non-positively charged amino acid residues in the pocket to positively charged amino acids (CpAgo_PM). In in vitro cleavage experiments, four different target sites (TET2-1 / 2 / 3 / 4) on the human TET2 gene transcript were tested. Compared with CpAgo_WT, CpAgo_PM significantly improves the cleavage efficiency at three sites: TET2-1, TET2-2, and TET2-4, indicating that it partially overcomes the sequence cleavage bias of the wild type. Furthermore, its gene editing function in a eukaryotic cell environment has been clearly demonstrated.

The invention discloses an MYB gene transcript detection primer combination for evaluating leukemia prognosis, a kit, a method and application of the MYB gene transcript detection primer combination. The primer combination comprises a first primer pair for specifically detecting an MYB TSS1 transcript and a second primer pair for detecting an MYB TSS2 transcript, and the nucleotide sequences of the first primer pair and the second primer pair are respectively shown as SEQ ID NO: 1-4. The amplification efficiency of the two pairs of primers is highly consistent. The kit containing the primer combination is simple and convenient to operate and suitable for clinical conventional use. The invention further provides a method for detecting the ratio of MYB TSS2 transcripts to TSS1 transcripts in a leukemia sample through real-time fluorescent quantitative PCR by using the primer or the kit, and evaluating the prognosis of a patient according to the ratio of the MYB TSS2 transcripts to the TSS1 transcripts. The ratio can be used as a novel molecular marker for predicting the refractory, drug resistance and recurrence risk of leukemia patients (especially myelogenous and gonorrhea leukemia). The invention provides an effective tool for precise prognosis stratification of leukemia.

This invention provides a method for assessing chicken aging based on the PDCD10 gene transcript and its application, belonging to the field of biodetection technology. This invention provides the application of the PDCD10 gene transcript as a marker of chicken aging, and the nucleotide sequence of the cDNA corresponding to the PDCD10 gene transcript is shown in SEQ ID No. 1. The PDCD10 gene transcript of this invention exhibits a continuous and linearly decreasing expression characteristic with increasing age in multiple chicken tissues, showing a consistent molecular change pattern across tissues during aging, which can more accurately reflect the overall physiological aging state of chickens, improving the stability and reliability of chicken aging assessment. This invention can be used for the graded assessment and dynamic monitoring of the aging state of chicken flocks, providing a molecular-level reference for flock management, culling timing selection, and adjustment of feeding strategies during the breeding process.

The present disclosure provides a method of treating retinitis pigmentosa type 11 (RP11) comprising administering to the eye of a subject a conjugate comprising a cell penetrating peptide (CPP) and an antisense oligonucleotide that modifies pre-mRNA splicing in the CNOT3 gene transcript and / or increases expression of a PRPF31 protein. Also disclosed are related pharmaceutical compositions and formulations thereof.

The present application relates to the technical field of high-throughput sequencing, and discloses a double-labeled primer system for nucleic acid library source quality control and application thereof. The existing DNA / RNA co-library technology cannot distinguish nucleic acid template sources, and the exogenous spike-in quality control method has the problems of interference risk, high cost and low efficiency. The present application provides a double-labeled primer system, which comprises: a first primer pair targeting the PCARE gene for specifically amplifying nucleic acid fragments of DNA origin; and a second primer pair targeting the IFT140 gene transcript variant X25 for specifically amplifying nucleic acid fragments of RNA origin. Based on the above system, by detecting the depth and ratio of the two amplicons in high-throughput sequencing, qualitative discrimination and quantitative monitoring of DNA and RNA source components in the nucleic acid library can be realized. The present application does not need to add exogenous sequences, and has the advantages of no interference, low cost and high accuracy.

To provide alternative compositions and methods for diagnosing and treating inflammatory bowel diseases such as ulcerative colitis.SOLUTION: It was concluded that the expression of a number of genes (determined by measuring changes in gene transcript biomarkers in colonic or rectal tissue samples) occurs in response to treatment with anti-IL-23pl9 antibodies in patients with or suspected of having ulcerative colitis. This gene transcript may be used as a biomarker for diagnosing ulcerative colitis, symptoms of ulcerative colitis, bowel frequency associated with ulcerative colitis, and bowel urgency associated with ulcerative colitis. Genetic transcripts may also be used as biomarkers of successful response to treatment with anti-IL - 23p19 antibodies.SELECTED DRAWING: None